VBI Vaccines

76 articles with VBI Vaccines

• VBI Vaccines to Present at the H.C. Wainwright Hepatitis B Virus (HBV) Mini-Conference

  10/15/2020

  VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that members of the management team will discuss VBI-2601, the Company’s vaccine immunotherapeutic candidate in development for a functional cure for hepatitis B (HBV) infection, in a fireside chat at the H.C. Wainwright Hepatitis B Virus (HBV) M

• VBI Vaccines Announces e-Poster Presentation at The Liver Meeting® 2020

  10/8/2020

  VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that its abstract highlighting data from the Phase 3 program evaluating Sci-B-Vac®, the company’s 3-antigen prophylactic hepatitis B (HBV) vaccine, was accepted for e-poster presentation at the American Association for the Study of Liver Diseases

• VBI Vaccines to Present at Upcoming Scientific Conferences

  9/24/2020

  VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced upcoming presentations

• VBI Vaccines Announces Biomarker Data From VBI-1901 Phase 1/2a Study in Recurrent GBM Presented at ESMO Virtual Congress 2020

  9/17/2020

  VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced additional biomarker data from its ongoing Phase 1/2a study evaluating VBI-1901, the company’s cancer vaccine immunotherapeutic candidate in recurrent glioblastoma (GBM) patients presented in an e-poster at The European Society for Medical Oncol

• VBI Vaccines to Present Additional Biomarker Data from VBI-1901 Phase 1/2a Study in Recurrent GBM in an E-Poster at ESMO Virtual Congress 2020

  9/14/2020

  VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that its abstract highlighting additional biomarker data from the ongoing Phase 1/2a study of VBI-1901, the company’s cancer vaccine immunotherapeutic candidate, in recurrent glioblastoma (GBM) patients was selected for an e-poster presentation

• VBI Vaccines Presents Phase 3 Sci-B-Vac® Data at EASL 2020

  8/31/2020

  VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the presentation of two abstracts featuring data from the Phase 3 program evaluating Sci-B-Vac®, the company’s tri-antigenic prophylactic hepatitis B (HBV) vaccine,

•  VBI Vaccines Announces Preclinical Coronavirus Program Data and Selection of Clinical Candidates with Potential as One-Dose Vaccines

  8/26/2020

    VBI Vaccines Announces Preclinical Coronavirus Program Data and Selection of Clinical Candidates with Potential as One-Dose Vaccines  - VBI-2901 and VBI-2902 selected as trivalent and monovalent coronavirus vaccine candidates, respectively, for an adaptive Phase 1/2 clinical study expected to begin around year-end 2020, subject to regulatory approvals - After one dose, compared to high-titer convalescent sera, preclinical data demonstrated 10x higher anti

• 

  Biopharma Update on the Novel Coronavirus: August 26

  8/26/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 26, 2020.

• VBI Vaccines Announces Multiple Phase 3 Sci-B-Vac® Abstracts Accepted for Oral and Poster Presentations at EASL 2020

  8/20/2020

  VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that two abstracts featuring data from the Phase 3 program evaluating Sci-B-Vac®, the company’s tri-antigenic prophylactic hepatitis B (HBV) vaccine, have been accepted for presentation at The Digital International Liver Congress TM 2020 (ILC),

• VBI Vaccines Announces Second Quarter 2020 Financial Results and Provides Corporate Update

  7/31/2020

  Productive pre-submission meetings with FDA and EMA in May and July 2020 expected to enable filings of regulatory approval applications for Sci-B-Vac ® in the U.S., Europe, and Canada beginning Q4 2020 Pre-clinical data for VBI-2901, VBI’s coronavirus program, expected to enable selection of clinical candidate(s) in Q3 2020 and the manufacturing of clinical study material, expected in Q4 2020 Additional clinical data expected for VBI’s therap

• VBI Vaccines Announces Data from VBI-1901 Presented at AACR 2020: Partial Response Observed, Promising Biomarker Strategy Identified

  6/22/2020

  Confirmed durable partial response with recurrent GBM tumor reduction of more than 50% - Normal baseline CD4+/CD8+ T cell ratio identified as potentially predictive biomarker associated with tumor responses - AACR data support further clinical development – exploring registrational study, expected to initiate 2021 CAMBRIDGE, Mass.--( BUSINESS WIRE )-- VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI") a commercial-stage biopharmaceutical company deve

• VBI Vaccines Announces Results of Annual General Meeting

  6/18/2020

  VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI" or the "Company"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the voting results from its annual general meeting of shareholders held on June 18, 2020 (the "Meeting").

• VBI Vaccines to Present at Upcoming Investor Conferences

  6/17/2020

  VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that members of the management team will participate in the following upcoming virtual investor conferences: Raymond James’ Human Health Innovation Conference - Presentation: Thursday, June 18, 2020 from 2:20-2:50 PM ET - Webcast

• VBI Vaccines Announces Formation of Commercial Advisory Board

  5/28/2020

  VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the formation of a Commercial Advisory Board consisting of leading experts in public health policy, epidemiology, and vaccine development. The Commercial Advisory Board will work closely with VBI’s management team on pre-commercialization and comm

• VBI Vaccines Secures $50 Million Debt Financing From K2 HealthVentures

  5/27/2020

  VBI Vaccines Inc., a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, announced that it has entered into a debt financing facility for up to $50 million with K2 HealthVentures, a healthcare-focused specialty finance company.

• VBI Vaccines Announces Upcoming Poster Presentation of Phase 1/2a data of VBI-1901 in Recurrent GBM Patients at AACR Virtual Annual Meeting

  5/15/2020

  Presentation will highlight expanded immunologic and tumor response data as well as potentially-predictive biomarker data from the VBI-1901 + GM-CSF study arm in Part B of the ongoing Phase 1/2a study E-Poster and accompanying recorded narrative will be available on June 22, 2020 CAMBRIDGE, Mass.--( BUSINESS WIRE )-- VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious di

• VBI Vaccines Announces First Quarter 2020 Financial Results and Provides Corporate Update 

  5/6/2020

  VBI Vaccines Announces First Quarter 2020 Financial Results and Provides Corporate Update  

• VBI Vaccines Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares - April 27, 2020

  4/27/2020

  VBI Vaccines Inc., a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, announced the closing of its previously announced underwritten public offering and the exercise in full of the underwriters’ option to purchase additional shares.

• VBI Vaccines Announces Pricing of $50 Million Public Offering

  4/22/2020

  VBI Vaccines Inc. (Nasdaq: VBIV) (VBI or the Company), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the pricing of its previously announced underwritten public offering of 45,454,545 common shares, at a public offering price of US$1.10 per share. VBI also granted the underwriters a 30-day option to purchase up to an additional 6

• VBI Vaccines Announces Proposed Public Offering of Common Shares - April 21, 2020

  4/21/2020

  VBI Vaccines Inc., a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, announced that it has commenced an underwritten public offering of its common shares.